These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10668853)

  • 21. Amino acid 305 determines catalytic center accessibility in CYP3A4.
    Fowler SM; Riley RJ; Pritchard MP; Sutcliffe MJ; Friedberg T; Wolf CR
    Biochemistry; 2000 Apr; 39(15):4406-14. PubMed ID: 10757990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease.
    Yu H; Anderson PJ; Freedman BI; Rich SS; Bowden DW
    Genomics; 2000 Oct; 69(2):225-34. PubMed ID: 11031105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.
    Lamba J; Strom S; Venkataramanan R; Thummel KE; Lin YS; Liu W; Cheng C; Lamba V; Watkins PB; Schuetz E
    Clin Pharmacol Ther; 2006 Apr; 79(4):325-38. PubMed ID: 16580901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.
    Lee SJ; van der Heiden IP; Goldstein JA; van Schaik RH
    Drug Metab Dispos; 2007 Jan; 35(1):67-71. PubMed ID: 17035598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.
    Fernandez-Salguero P; Hoffman SM; Cholerton S; Mohrenweiser H; Raunio H; Rautio A; Pelkonen O; Huang JD; Evans WE; Idle JR
    Am J Hum Genet; 1995 Sep; 57(3):651-60. PubMed ID: 7668294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.
    Hustert E; Zibat A; Presecan-Siedel E; Eiselt R; Mueller R; Fuss C; Brehm I; Brinkmann U; Eichelbaum M; Wojnowski L; Burk O
    Drug Metab Dispos; 2001 Nov; 29(11):1454-9. PubMed ID: 11602521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 (CYP3A4*18) and glutathione-S-transferase (GSTP1) polymorphisms in a healthy Tunisian population.
    Zaied C; Abid S; Mtiraoui N; Zellema D; Achour A; Bacha H
    Genet Test Mol Biomarkers; 2012 Oct; 16(10):1184-7. PubMed ID: 22971138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.
    van Schaik RH; de Wildt SN; van Iperen NM; Uitterlinden AG; van den Anker JN; Lindemans J
    Clin Chem; 2000 Nov; 46(11):1834-6. PubMed ID: 11067821
    [No Abstract]   [Full Text] [Related]  

  • 32. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
    Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
    Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4.
    Roussel F; Khan KK; Halpert JR
    Arch Biochem Biophys; 2000 Feb; 374(2):269-78. PubMed ID: 10666307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.
    Du J; Xing Q; Xu L; Xu M; Shu A; Shi Y; Yu L; Zhang A; Wang L; Wang H; Li X; Feng G; He L
    Pharmacogenomics; 2006 Sep; 7(6):831-41. PubMed ID: 16981844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects.
    Ruzilawati AB; Suhaimi AW; Gan SH
    Clin Chim Acta; 2007 Aug; 383(1-2):158-62. PubMed ID: 17601520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
    Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.
    Ariyoshi N; Takahashi Y; Miyamoto M; Umetsu Y; Daigo S; Tateishi T; Kobayashi S; Mizorogi Y; Loriot MA; Stücker I; Beaune P; Kinoshita M; Kamataki T
    Pharmacogenetics; 2000 Nov; 10(8):687-93. PubMed ID: 11186131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.